Welcome to our dedicated page for TriSalus Life Sciences news (Ticker: TLSI), a resource for investors and traders seeking the latest updates and insights on TriSalus Life Sciences stock.
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) is an oncology-focused medical technology company whose news flow centers on its Pressure-Enabled Drug Delivery (PEDD) platform, TriNav infusion systems and the clinical and commercial progress of its solid tumor programs. Company updates frequently highlight revenue trends tied to adoption of the TriNav product suite in liver-directed therapies, as well as broader use of PEDD-based embolization techniques in new clinical settings.
Investors and observers following TLSI news can expect regular earnings releases and operational updates that discuss net sales from the TriNav system, gross margin dynamics, operating expenses and changes in capital structure, including exchange offers and preferred stock conversions described in SEC filings. These releases often emphasize growing clinical adoption of PEDD technology across a range of solid tumor indications and note the company’s focus on the interventional radiology specialty.
TriSalus also issues news about clinical and scientific developments. Examples include publication of data on Pressure-Enabled Thyroid Artery Embolization (PED-TAE) using the TriNav Infusion System for symptomatic thyroid disease, initiation of a clinical trial evaluating genicular artery embolization for knee osteoarthritis, and registry efforts such as the PROTECT study. The company additionally announces key opinion leader events that review the use of TriNav in thyroid and uterine artery embolization and discuss unmet needs in these areas.
Another recurring category of TLSI news involves participation in healthcare and growth conferences, where management provides corporate overviews and meets with investors. Together, these earnings updates, clinical data announcements, KOL events and conference appearances provide a detailed view of how TriSalus is advancing and commercializing its PEDD technology and investigational immunotherapy. Bookmarking the TLSI news page offers a centralized way to follow these developments over time.
TriSalus Life Sciences (Nasdaq: TLSI) will host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss first quarter 2026 financial results for the quarter ended March 31, 2026. A press release with results will be issued before the call.
Dial-in registration is required; webcast and replay will be available on the company investor relations website.
TriSalus Life Sciences (Nasdaq: TLSI) will present new clinical and preclinical data at the SIR 2026 Annual Scientific Meeting April 11–15, 2026 in Toronto. Presentations on April 13–14 showcase the Pressure Enabled Drug Delivery™ (PEDD™) platform across liver, pancreatic and uterine applications.
The company highlighted investigator and preclinical work and noted nearing completion of multiple Phase 1 data sets and upcoming partnership discussions.
TriSalus Life Sciences (Nasdaq: TLSI) appointed Richard Marshall, M.D., as Chief Medical Officer, effective June 29, 2026. Dr. Marshall transitions from Medical Director (since January 2025) and will lead medical strategy, clinical development, evidence generation and broader strategic initiatives for the company’s PEDD platform and TriNav product suite.
The appointment signals continued leadership strengthening as TriSalus pursues clinical and economic advantages for its pressure-enabled drug delivery approach across solid tumors.
TriSalus Life Sciences (Nasdaq: TLSI) published preclinical data showing that Pressure-Enabled Drug Delivery (PEDD) with the TriNav® Infusion System improved intratumoral distribution and immune activation of nelitolimod in liver tumor models.
Key findings include greater tumor distribution versus microcatheter delivery, reduced myeloid-derived suppressor cells, increased CD8+ T cell infiltration, and reduced tumor growth in murine metastasis models.
TriSalus (Nasdaq: TLSI) reported strong commercial growth in Q4 2025 with $13.2M revenue (+60% y/y) and full-year $45.2M revenue (+53% y/y). The company raised $46M gross proceeds in a public offering, improved adjusted EBITDA, and reaffirmed 2026 revenue guidance of $60–62M.
Management cited product launches, expanded TriNav adoption, and planned commercial investments to support 2026 growth and broader PEDD platform adoption.
TriSalus Life Sciences (Nasdaq: TLSI) will host a conference call and webcast on Thursday, March 5, 2026 at 4:30 PM Eastern to discuss financial results for the quarter ended December 31, 2025. A press release with results will be issued before the call.
Participants can register for phone access and the webcast; a replay will be available on the investor relations website after the event.
TriSalus Life Sciences (Nasdaq: TLSI) priced an underwritten public offering of 9,756,100 common shares at $4.10 per share, with gross proceeds of approximately $40.0 million.
The company granted the underwriter a 30-day option to purchase up to 1,463,415 additional shares (15%). The offering is expected to close on or about February 23, 2026, subject to customary closing conditions.
TriSalus Life Sciences (Nasdaq: TLSI) announced its intent to sell shares of common stock in an underwritten public offering, with all shares to be sold by the company. TriSalus intends to grant underwriters a 30-day option to purchase up to 15% of the offering.
Lake Street Capital Markets is the sole book-runner. The offering is made from an effective Form S-3 shelf registration (File No. 333-291509) declared effective December 4, 2025, and is subject to market conditions; final terms will be disclosed in a prospectus supplement.
TriSalus Life Sciences (Nasdaq: TLSI) announced a board change effective February 4, 2026: Dr. Arjun “JJ” Desai resigned and Michael P. Stansky was appointed to the Board.
Mr. Stansky brings 40 years of investment and healthcare experience, prior roles at Tudor Investment and Wellington, current board seats at Insightec and Momentis Surgical, and credentials as a CPA and CFA.
TriSalus Life Sciences (Nasdaq: TLSI) reported preliminary unaudited results for Q4 and full-year 2025. Q4 2025 revenue was approximately $13.2 million (≈60% YoY) and full-year 2025 revenue was approximately $45.2 million (≈53% YoY), exceeding 2025 guidance. Year-end cash and cash equivalents were approximately $20.4 million, down $2.3 million from the start of Q4. The company set initial 2026 revenue guidance of approximately $60–$62 million. Results are preliminary, unaudited and subject to change pending year-end close and audit.